Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 1.18
(-1.26%)
SEK 1.18
(-1.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 73.12 Million SEK | -39.2% |
| 2022 | 120.27 Million SEK | 1.66% |
| 2021 | 118.3 Million SEK | -10.65% |
| 2020 | 132.4 Million SEK | 30.16% |
| 2019 | 101.72 Million SEK | -4.26% |
| 2018 | 106.25 Million SEK | -31.83% |
| 2017 | 155.87 Million SEK | -3.8% |
| 2016 | 162.03 Million SEK | -8.39% |
| 2015 | 176.88 Million SEK | 353664.0% |
| 2014 | 50 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 69.01 Million SEK | -5.62% |
| 2024 Q2 | 65.77 Million SEK | -4.69% |
| 2023 Q1 | 95.47 Million SEK | -20.62% |
| 2023 Q2 | 85.38 Million SEK | -10.57% |
| 2023 Q3 | 76.01 Million SEK | -10.97% |
| 2023 Q4 | 73.12 Million SEK | -3.81% |
| 2023 FY | 73.12 Million SEK | -39.2% |
| 2022 Q3 | 91.42 Million SEK | -10.13% |
| 2022 FY | 120.27 Million SEK | 1.66% |
| 2022 Q2 | 101.72 Million SEK | -13.43% |
| 2022 Q1 | 117.5 Million SEK | -0.68% |
| 2022 Q4 | 120.27 Million SEK | 31.56% |
| 2021 Q3 | 119.18 Million SEK | -12.43% |
| 2021 Q2 | 136.09 Million SEK | -7.14% |
| 2021 FY | 118.3 Million SEK | -10.65% |
| 2021 Q1 | 146.55 Million SEK | 10.69% |
| 2021 Q4 | 118.3 Million SEK | -0.73% |
| 2020 Q2 | 128.28 Million SEK | 0.47% |
| 2020 FY | 132.4 Million SEK | 30.16% |
| 2020 Q4 | 132.4 Million SEK | 6.25% |
| 2020 Q1 | 127.68 Million SEK | 25.52% |
| 2020 Q3 | 124.61 Million SEK | -2.86% |
| 2019 Q3 | 110.15 Million SEK | 1.64% |
| 2019 Q2 | 108.37 Million SEK | 3.03% |
| 2019 Q1 | 105.19 Million SEK | -1.0% |
| 2019 FY | 101.72 Million SEK | -4.26% |
| 2019 Q4 | 101.72 Million SEK | -7.65% |
| 2018 Q1 | 152.54 Million SEK | -2.13% |
| 2018 Q3 | 143.84 Million SEK | -2.34% |
| 2018 FY | 106.25 Million SEK | -31.83% |
| 2018 Q4 | 106.25 Million SEK | -26.13% |
| 2018 Q2 | 147.29 Million SEK | -3.45% |
| 2017 Q2 | 162.11 Million SEK | 1.56% |
| 2017 FY | 155.87 Million SEK | -3.8% |
| 2017 Q1 | 159.61 Million SEK | -1.49% |
| 2017 Q4 | 155.87 Million SEK | -2.94% |
| 2017 Q3 | 160.59 Million SEK | -0.94% |
| 2016 Q4 | 162.03 Million SEK | -1.71% |
| 2016 FY | 162.03 Million SEK | -8.39% |
| 2016 Q3 | 164.85 Million SEK | -2.28% |
| 2016 Q2 | 168.69 Million SEK | -2.84% |
| 2016 Q1 | 173.63 Million SEK | -1.84% |
| 2015 FY | 176.88 Million SEK | 353664.0% |
| 2015 Q3 | 178.95 Million SEK | 0.0% |
| 2015 Q4 | 176.88 Million SEK | -1.16% |
| 2014 FY | 50 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -24.976% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -128.493% |
| BioGaia AB (publ) | 2.33 Billion SEK | 96.866% |
| Enzymatica AB (publ) | 125.91 Million SEK | 41.927% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -112.651% |
| Gabather AB (publ) | 2.93 Million SEK | -2389.615% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | 88.48% |
| Nanexa AB (publ) | 132.25 Million SEK | 44.714% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | 19.534% |
| ODI Pharma AB | 12.27 Million SEK | -495.683% |
| Orexo AB (publ) | 786.6 Million SEK | 90.704% |
| Probi AB (publ) | 1.55 Billion SEK | 95.284% |
| Swedencare AB (publ) | 9.52 Billion SEK | 99.232% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.901% |
| Toleranzia AB | 160.42 Million SEK | 54.422% |
| Vivesto AB | 355.87 Million SEK | 79.454% |